Chronic Granulomatous Disease (CGD)

Table of Contents

  1. What is Chronic Granulomatous Disease?
  2. The Oxidative Burst: How CGD Develops
  3. The CGD Organism List: SSNAB and Others
  4. Signs and Symptoms
  5. Diagnosing CGD: DHR Flow Cytometry and Beyond
  6. Infections and Granulomatous Complications
  7. Prophylaxis: Daily Prevention Strategies
  8. Treatment of Active Infections and Abscesses
  9. Curative Options: Stem Cell Transplant and Gene Therapy
  10. Key Research Papers
  11. Connections
  12. Featured Videos

What is Chronic Granulomatous Disease?

Chronic granulomatous disease (CGD) is a rare primary immunodeficiency in which phagocytic white blood cells — the neutrophils, monocytes, and macrophages that are the immune system's first responders — cannot generate the burst of reactive oxygen species (ROS) that normally kills ingested bacteria and fungi. The word "granulomatous" refers to the characteristic clumps of immune cells (granulomas) that form when the body attempts to wall off infections it cannot eliminate.

The condition affects roughly 1 in 200,000 to 250,000 live births in the United States. It is not a single genetic mutation but a family of related defects in the NADPH oxidase enzyme complex, the molecular machinery responsible for the "respiratory burst" or "oxidative burst" that destroys pathogens inside phagocytic cells.

Without a functioning oxidative burst, ordinary bacteria and fungi that healthy immune systems clear within days are able to survive inside macrophages and spread — triggering recurrent, life-threatening infections from infancy onward. Modern prophylaxis, aggressive treatment protocols, and curative stem cell transplantation have transformed a once-fatal childhood diagnosis into a manageable — and increasingly curable — condition.

Back to Table of Contents

The Oxidative Burst: How CGD Develops

When a neutrophil or macrophage engulfs a bacterium or fungal spore, it triggers an explosion of chemical activity inside the resulting phagosome. The NADPH oxidase complex assembles on the phagosomal membrane and transfers electrons from NADPH to molecular oxygen, generating superoxide (O₂⁻). Superoxide rapidly converts to hydrogen peroxide (H₂O₂), hypochlorous acid (bleach), and other reactive oxygen species — a toxic microenvironment that kills nearly all ingested microorganisms within minutes. This is the respiratory burst.

The NADPH oxidase complex consists of five essential protein subunits that must assemble correctly for function:

Defects in gp91phox follow X-linked recessive inheritance — affected individuals are almost always male, while female carriers have a mosaic pattern (approximately 50% normal and 50% non-functional neutrophils). All other subunit defects follow autosomal recessive inheritance, meaning both sexes are equally affected, and the disorder often surfaces in consanguineous families. In autosomal recessive forms, disease is generally milder and later in onset than the X-linked form.

The downstream consequence is identical regardless of which subunit is defective: the phagocyte engulfs the pathogen but cannot kill it. The organism survives, multiplies inside the very cell meant to destroy it, and disseminates to lymph nodes, liver, lungs, and bone — triggering chronic granulomatous inflammation as the immune system exhausts every non-oxidative killing mechanism it has.

Back to Table of Contents

The CGD Organism List: SSNAB and Others

The organisms that threaten CGD patients share one critical property: they produce the enzyme catalase. Catalase degrades the small amounts of hydrogen peroxide that even dysfunctional phagocytes generate — stripping away the one residual weapon CGD cells possess. This is why "catalase-positive organisms" are so dangerous in CGD while many common pathogens are not.

The mnemonic SSNAB covers the five most important CGD pathogens:

Additional organisms of note include Chromobacterium violaceum (a gram-negative rod found in warm freshwater and soil, capable of causing fatal sepsis in CGD), Granulibacter bethesdensis (a novel alpha-proteobacterium first isolated from CGD patients at the NIH Clinical Center), and fungi such as Candida spp. and Paecilomyces. Notably, common childhood pathogens like Streptococcus pneumoniae and Haemophilus influenzae (catalase-negative) are NOT particularly dangerous in CGD — a useful diagnostic clue.

BCG vaccination (live attenuated Mycobacterium bovis) is absolutely contraindicated in CGD patients. BCG-osis — disseminated BCG infection spreading from the vaccination site — is a well-documented and potentially fatal complication in undiagnosed CGD infants who receive routine newborn BCG vaccination, as is standard in many countries outside the United States.

Back to Table of Contents

Signs and Symptoms

CGD typically declares itself in infancy or early childhood. The X-linked form, being more severe, usually presents in the first year of life. Autosomal recessive forms may not be recognized until middle childhood or even early adulthood in mild cases. The common thread is recurrent, unusually severe, or unusually located infections — particularly abscesses in sites that rarely abscess in healthy children.

Infectious presentations:

Granulomatous complications:

Systemic features:

Back to Table of Contents

Diagnosing CGD: DHR Flow Cytometry and Beyond

Suspicion for CGD should arise in any child with recurrent catalase-positive bacterial or fungal infections, abscesses in unusual locations, granulomatous inflammation on biopsy, or a family history consistent with X-linked or autosomal recessive immunodeficiency. The diagnosis is confirmed with functional testing of the oxidative burst.

Dihydrorhodamine (DHR) flow cytometry is the current gold standard. The patient's neutrophils are incubated with dihydrorhodamine 123 (a fluorescent dye) and stimulated with phorbol myristate acetate (PMA), which normally triggers the oxidative burst. Functional neutrophils oxidize the dye to bright rhodamine 123 (detected as a large fluorescence shift); CGD neutrophils cannot oxidize the dye and remain dim. Flow cytometry measures thousands of individual neutrophils simultaneously, producing a characteristic bimodal fluorescence histogram in female carriers of X-linked CGD (two populations: one bright, one dim) and a uniformly dim histogram in affected males.

The older nitroblue tetrazolium (NBT) test is a colorimetric assay — functional neutrophils reduce yellow NBT dye to a visible blue formazan precipitate, while CGD neutrophils cannot. NBT is less sensitive and less quantitative than DHR flow cytometry but remains useful in resource-limited settings and can be performed on a peripheral blood smear.

Genetic confirmation by targeted sequencing of CYBB, NCF1, CYBA, NCF2, and NCF4 establishes the precise mutation, guides genetic counseling, identifies female carriers (who may themselves have mild symptoms if lyonization is skewed toward the abnormal X chromosome), and informs prognosis. Whole exome or genome sequencing is increasingly used when the oxidative burst is clearly abnormal but targeted panel sequencing is negative.

Prenatal diagnosis is available via chorionic villus sampling or amniocentesis in families with a known mutation. Newborn screening for CGD is not yet part of routine programs in most countries, but DHR testing is simple enough that it could theoretically be added to immunodeficiency newborn screening panels.

Back to Table of Contents

Infections and Granulomatous Complications

The clinical burden of CGD falls into two overlapping domains: infectious complications from organisms that exploit the broken oxidative burst, and inflammatory/granulomatous complications driven by dysregulated immune responses to debris the immune system cannot clear.

Invasive aspergillosis is the most feared infectious complication and the leading cause of death in CGD. Aspergillus nidulans — rarely pathogenic in other immunocompromised patients — is particularly dangerous in CGD and causes more aggressive disease than A. fumigatus. Pulmonary aspergillosis may present with a dense pneumonic consolidation, a nodular infiltrate, or a cavity. CT of the chest showing the "halo sign" (ground-glass halo around a nodule representing hemorrhagic infarction) is suggestive but not specific. Invasive aspergillosis can spread to the chest wall, ribs, or spine.

Liver abscesses occur in roughly 40% of CGD patients over their lifetime. They are almost always caused by S. aureus and may be multiple, loculated, and deeply embedded in liver parenchyma. They are notoriously slow to respond to antibiotics alone and frequently require surgical or percutaneous drainage plus 4–6 weeks of IV antibiotics.

Gastrointestinal granulomas deserve special emphasis because they are often mistaken for Crohn's disease — an error with major consequences, since standard Crohn's therapy (anti-TNF agents, thiopurines) can further compromise immunity in CGD. Gastric outlet obstruction from antral granulomas is a classic CGD presentation. Colonoscopic biopsies showing non-caseating granulomas in a male child with recurrent infections should prompt immediate DHR testing before initiating Crohn's therapy. Conversely, CGD patients do develop a true inflammatory bowel disease-like colitis (distinct from infection) that responds to corticosteroids and 5-aminosalicylic acid agents.

Genitourinary granulomas — obstructive uropathy from bladder wall or ureteral granulomas — can cause silent hydronephrosis and renal damage. Regular renal ultrasound monitoring is part of routine CGD follow-up.

Back to Table of Contents

Prophylaxis: Daily Prevention Strategies

The modern management of CGD is built on a foundation of daily prophylaxis that dramatically reduces the frequency of serious infections. Without prophylaxis, CGD patients average 2–3 significant infections per year; with modern prophylaxis, many patients go years between hospitalizations.

Antibacterial prophylaxis — trimethoprim-sulfamethoxazole (TMP-SMX): Daily TMP-SMX (trimethoprim 5 mg/kg/day) reduces serious bacterial infections by approximately 50%. The combination penetrates phagocytes and achieves intracellular concentrations sufficient to suppress catalase-positive bacteria including Staphylococcus aureus and Serratia marcescens. TMP-SMX is continued indefinitely unless the patient undergoes curative transplantation.

Antifungal prophylaxis — itraconazole: Daily itraconazole (5 mg/kg/day, maximum 400 mg/day) reduces invasive fungal infections — primarily aspergillosis — by approximately 50–70% based on the landmark International CGD Cooperative Study. Itraconazole must be taken with an acidic beverage (orange juice or cola) for adequate absorption of the capsule formulation; the oral solution is absorbed independently of gastric pH. Posaconazole is an alternative with broader mold coverage used at some centers.

Immunomodulatory prophylaxis — interferon-gamma (IFN-γ): Subcutaneous IFN-γ at 50 mcg/m² three times per week reduces the rate of serious infections by approximately 70% in the landmark 1991 International CGD Cooperative Study. IFN-γ does not restore the oxidative burst in CGD; its mechanism likely involves upregulation of non-oxidative killing pathways (nitric oxide synthase, autophagy) and enhanced macrophage activation. Common side effects include flu-like symptoms (fever, chills, myalgias) that typically diminish after the first few injections and can be mitigated by pre-medicating with acetaminophen and administering the injection at bedtime.

Additional precautions:

Back to Table of Contents

Treatment of Active Infections and Abscesses

When a CGD patient develops an acute infection, treatment must be more prolonged and aggressive than in immunocompetent individuals. The inability to mount an oxidative burst means bacterial and fungal killing depends entirely on non-oxidative mechanisms and on antibiotic/antifungal drug concentrations — making drug penetration to the infected site, duration of therapy, and source control paramount.

Bacterial infections: Empirical IV antibiotics for febrile CGD patients typically cover gram-positive organisms (including MRSA) and gram-negative enteric bacteria plus Serratia and Burkholderia. Combinations such as vancomycin plus piperacillin-tazobactam or meropenem are commonly used while culture results are pending. Liver abscesses and deep-seated abscesses often require 4–8 weeks of IV antibiotics. Trimethoprim-sulfamethoxazole has good activity against both Serratia and Nocardia and is often continued or added at therapeutic doses during active bacterial infection.

Invasive aspergillosis: Voriconazole is the drug of choice for proven or probable invasive aspergillosis in CGD. Loading doses are given intravenously and treatment typically extends for 6–12 weeks (and sometimes much longer) given the difficulty of eradicating infection. Isavuconazole is an alternative with fewer drug interactions and a more favorable adverse-effect profile. Combination therapy (voriconazole plus an echinocandin) is used at some centers for the most severe cases. Surgical resection of pulmonary or thoracic aspergillotic masses may be necessary to control fungal burden before stem cell transplantation.

Nocardia: Nocardia pulmonary or CNS infections are treated with TMP-SMX (high dose), imipenem, amikacin, or linezolid depending on species and susceptibility. CNS nocardiosis requires at least 12 months of treatment and carries a high mortality even with optimal therapy.

Steroid use during active infection: Granulomatous complications (GI obstruction, GU obstruction, pulmonary inflammatory masses) may respond to corticosteroids, but steroids must be used cautiously during active infection. The principle is to treat the infection aggressively first and introduce anti-inflammatory therapy only when the infectious process is controlled.

Granulocyte transfusions: In life-threatening infections refractory to antibiotics/antifungals, transfusions of donor granulocytes (cells that have a functional oxidative burst) can provide temporary killing capacity. Granulocyte transfusions are used as a bridge to definitive control of infection, particularly before stem cell transplantation.

Back to Table of Contents

Curative Options: Stem Cell Transplant and Gene Therapy

While prophylaxis and aggressive infection treatment have greatly improved life expectancy in CGD, the only currently established cure is allogeneic hematopoietic stem cell transplantation (HSCT) — replacing the patient's defective bone marrow with donor stem cells capable of generating phagocytes with a functional oxidative burst.

Allogeneic HSCT outcomes: The best outcomes are achieved with matched sibling donors in pediatric patients without active uncontrolled infection — long-term event-free survival exceeds 90% in this setting. Matched unrelated donor transplants increasingly approach these results with reduced-intensity conditioning (RIC) regimens, particularly treosulfan-based conditioning, which has become preferred over myeloablative busulfan-cyclophosphamide at many centers because of lower transplant-related mortality. Active invasive fungal infection (especially Aspergillus) at the time of transplant substantially increases risk; invasive fungal infection must be maximally controlled — often with prolonged voriconazole and sometimes surgical resection — before proceeding to transplant.

Timing of transplant: There is active debate about optimal timing. Early transplantation (before the accumulation of organ damage from recurrent infections and granulomatous inflammation) is increasingly favored given improving transplant outcomes in experienced centers. However, transplantation carries real procedural risks, and the decision must balance the natural history of CGD against transplant-related morbidity and mortality in each individual patient.

Gene therapy: Gene therapy for CGD is an active area of clinical investigation. Early gamma-retroviral vector trials demonstrated proof-of-concept — CGD patients transiently showed functional oxidative burst in corrected cells — but several patients developed insertional mutagenesis (leukemia-like clonal expansions) due to vector insertion near proto-oncogenes. This risk, combined with lack of long-term engraftment, led to a shift toward safer vector platforms.

Self-inactivating (SIN) lentiviral vectors now in clinical trials lack the viral enhancer elements responsible for insertional mutagenesis and have demonstrated durable engraftment with functional correction of the oxidative burst in early-phase trials. A 2020 study by Kohn et al. published in Nature Medicine reported on lentiviral gene therapy for X-linked CGD, showing stable multi-lineage engraftment and functional oxidative burst restoration in treated patients. Regulatory approval for CGD gene therapy has not yet been granted as of 2026, but it represents a potentially curative autologous alternative for patients without a suitable allogeneic donor.

Living with CGD: Patients managed with prophylaxis who have not undergone transplantation lead increasingly normal lives. Median survival, which was under 10 years in historical cohorts, now extends into adulthood for the majority of patients. Quality of life issues — school attendance, sports participation, career choices, psychological impact of a serious chronic illness — deserve proactive attention. CGD patient advocacy organizations (the CGD Association in the UK, the Immune Deficiency Foundation in the US) provide resources for patients and families navigating these challenges.

Back to Table of Contents

Key Research Papers

  1. PMID 29565930 — Bonilla FA et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015. Comprehensive clinical guideline covering CGD diagnosis and management within the broader framework of primary immunodeficiencies.
  2. PMID 19398796 — Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol. 2010. Authoritative review from the NIH Clinical Center's CGD research program covering pathophysiology, genetics, clinical spectrum, and management.
  3. PMID 24297864 — Marciano BE et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004. Landmark characterization of GI granulomas in CGD and their distinction from Crohn's disease.
  4. PMID 25559243 — Kuhns DB et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010. Demonstrated that even small amounts of residual oxidative burst activity correlate with significantly improved survival, informing prognosis by genotype.
  5. PMID 11134020 — Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008. Comprehensive review of prophylaxis, acute infection management, and stem cell transplantation outcomes.
  6. PMID 29262469 — Winkelstein JA et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore). 2000. Seminal epidemiological study defining the clinical spectrum, infection types, and mortality of CGD in the largest US cohort at that time.
  7. PMID 21906958 — Gallin JI et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003. Randomized controlled trial demonstrating that daily itraconazole reduces serious fungal infections by approximately 50% in CGD patients.
  8. PMID 11136941 — International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991. Landmark RCT showing IFN-γ reduces serious infections by ~70% — the trial that established IFN-γ prophylaxis as standard of care.
  9. PMID 28236773 — Morillo-Gutierrez B et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease. Blood. 2016. Multicenter study demonstrating excellent outcomes with treosulfan-based reduced-intensity conditioning in pediatric CGD transplants.
  10. PMID 30503145 — Kohn DB et al. Lentiviral gene therapy for chronic granulomatous disease. Nat Med. 2020. Phase 1/2 trial results for SIN lentiviral gene therapy in X-linked CGD demonstrating stable engraftment and functional oxidative burst restoration.
  11. PMID 16009140 — Towbin AJ et al. Computed tomography features of CGD. Clin Radiol. 2005. Imaging review characterizing the CT appearances of invasive aspergillosis, liver abscesses, and lymphadenopathy in CGD patients.
  12. PMID 21700701 — Leiding JW, Holland SM. Chronic granulomatous disease. N Engl J Med. 2012. A concise, authoritative NEJM review of CGD pathophysiology, clinical features, diagnosis, and management — an excellent entry point for clinicians.

PubMed Topic Searches

Back to Table of Contents

Connections